CannaTech

JANUARY 16, 2019

Thanks to the recent emergence of regulated medical cannabis markets, the success of this versatile plant can be followed from farm to pharma and prescriber to patient, however, the origins of cannabis as medicine cannot be as simply traced as the plant is today from seed to sale. Of course, patients need product and product costs money.

Access 89

Access Patients Pharmaceutical Education 89

Kind Meds (Cannabis Education Blog)

JUNE 27, 2021

At the same time, the pharmaceutical industry has become one of the most powerful businesses in the country. Big Pharma, which includes ten of the largest powers of the pharmaceutical industry, like businesses such as Johnson & Johnson, are heavily influential when it comes to political decisions in the U.S. Nerve pain.

Pharmaceutical 99

Pharmaceutical Chronic Pain Medicine Nerve Pain 99

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

DECEMBER 11, 2021

. 'A monumental shame' @AndyMcDonaldMP continuing to highlight how families continue to be passed from pillar to post as the Government fail to continue to tackle the necessary barriers to widen access to life-saving #medicalcannabis prescriptions. pic.twitter.com/hACy4b79yH. — End Our Pain (@End_Our_Pain) December 10, 2021.

Treatment 52

Treatment Access Patients Medicine 52

Cannabis Law Report

AUGUST 22, 2021

. “The Janus particle solution will allow for time-released and combined therapies to be administered to patients, targeting specific indications. is using cutting-edge delivery technologies to develop safe and effective psychedelic pharmaceutical medicines. ” About Psycheceutical, Inc. Psycheceutical, Inc.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. But in the years since 2017, lawmakers have steadily improved Virginia’s medical marijuana program and made it accessible to a wider range of people. Recently, Virginia legalization has changed in several ways.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. About 85% of these patients experience epilepsy as an effect of the condition, and more than half are unable to achieve seizure control.

Access 98

Access Epilepsy Treatment Conditions 98

Cannabis Law Report

JUNE 23, 2021

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S).

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

DECEMBER 15, 2021

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

Pharmaceutical 52

Pharmaceutical Cannabinoids Business Extraction 52

Cannabis Law Report

JUNE 1, 2022

This acquisition will accelerate Khiron’s growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies. Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

SpeedWeed

APRIL 9, 2021

Although this survey is specifically focused on Texas’ medical marijuana program, it also supports other research showing that cannabis can serve as an effective replacement for pharmaceuticals. This law allows a limited number of patients to use CBD-based medicine with no more than 0.5 percent THC content. View original article.

Pharmaceutical 52

Pharmaceutical Chronic Pain Programs Patients 52

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

NORML

JULY 1, 2019

Three new laws intended to expand patient access to and the therapeutic value of Virginia’s medical cannabis program take effect July 1, 2019. “These bills help ensure that all patients are able to obtain and use the necessary therapeutic doses of their cannabis medicines regardless of location or physical ability.”

Law 253

Law Patients Access Oil 253

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

The Cannigma

SEPTEMBER 21, 2021

There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.

Patients 94

Patients Research and Development Sleep Clinical Trials 94

Veriheal

JUNE 22, 2021

Sue Sisley was quoted telling media, “there are thousands of different cannabis varieties that all have unique chemical profiles and produce unique clinical effects, but we didn’t have access to that normal diversity.” Another company that will be cultivating cannabis for research is a pharmaceutical research company.

DEA 60

DEA Access Therapy Cannabinoids 60

Cannabis Law Report

SEPTEMBER 22, 2022

The Federal Parliament legalised the use of medicinal cannabis products in Australia in February 2016, but access to treatment is still severely limited due to cost, with patients reporting average monthly costs in excess of $300 , or approximately $10 per day. List Medicinal Cannabis on the PBS.

Pharmaceutical 52

Pharmaceutical Media Medicine Treatment 52

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

MMJ Recs

FEBRUARY 3, 2024

In recent years, the landscape of medical marijuana laws has evolved, presenting new opportunities and challenges for patients, healthcare providers, and industry stakeholders. Understanding these regulations is crucial for patients, caregivers, and dispensaries alike to ensure compliance with the law.

Legislation 52

Legislation Law Marijuana Dispensary 52

Cannabis Law Report

MAY 2, 2023

Australian cannabis company Cannatrek has launched a not-for-profit organisation dedicated to providing support and access to medicinal cannabis therapies for vulnerable groups. Medicinal cannabis is still quite expensive, […]

Therapy 52

Therapy Pharmaceutical Medicine Treatment 52

Cannabis Law Report

JANUARY 18, 2022

Texas Original Compassionate Cultivation assembled a focus group of veterans suffering from PTSD to evaluate symptom response, product preference and effects on supplemental pharmaceutical consumption. To learn whether you or a loved one qualifies for medical cannabis, visit www.texasoriginal.com/patients. Emma Chase.

Patients 52

Patients Tincture Pharmaceutical Cultivation 52

NORML

FEBRUARY 23, 2020

Legislation is pending, Senate Bill 165, to establish a medical marijuana access program for qualified patients with a physician’s recommendation to access medical marijuana from licensed retail outlets. Send a message to your lawmakers in support of medical marijuana access. AL resident? AZ resident? California.

Legislation 239

Legislation Patients Decriminalization Access 239

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. The society launched a campaign with the hashtag #ApprovedButDenied protesting the difficulty so many patients have faced attempting to obtain medical cannabis. ApprovedButDenied.

Treatment 98

Treatment Patients Access Research and Development 98

LifeCannMD

NOVEMBER 24, 2023

You will need to receive a new patient evaluation from a Florida-certified Medical Marijuana doctor in order to determine your eligibility and give a medical marijuana recommendation. Patients love that it is from mother nature and is a less addictive alternative to pharmaceutical drugs with major side effects.

Marijuana 52

Marijuana Chronic Pain Conditions Strains 52

SpeedWeed

MARCH 13, 2021

Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation. Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. More Than 1,000 PD Patients Surveyed.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

JULY 21, 2022

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Kabir Nath as Chief Executive Officer, effective August 1, 2022. London, UK July 19, 2022.

Therapy 52

Therapy Research and Development Pharmaceutical Patients 52

United Patients Group

JANUARY 4, 2024

As we move forward into 2024 and beyond, the sector offers diverse paths beyond direct patient care. The growth stems from rising healthcare demand, facility expansion, and the imperative for efficient administration to maintain quality patient care. Adverse drug events (ADEs) affect approximately 7 per 100 hospitalized patients.

Research and Development 52

Research and Development Patients Data Policy 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

NewsMunchies

JULY 10, 2023

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds major potential to increase the accessibility of drugs and to treat diseases and conditions. AI automation opens up the possibility of faster, cheaper pharmaceuticals. This, in turn, makes it possible to move fast without breaking things.

Treatment 58

Treatment Research and Development Pharmaceutical Microdosing 58

MMJ Recs

MARCH 23, 2024

Legalization may offer expanded access to medical cannabis for patients suffering from various conditions, providing alternative treatment options and symptom relief. However, challenges remain in ensuring equitable access to participation in the legal cannabis market and addressing disparities in ownership and representation.

Legalization 52

Legalization Access Programs Education 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S. Christy Curran.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

MGC Pharma

FEBRUARY 21, 2018

Armed with a well-developed agricultural sector, high environmental standards, world class pharmaceutical manufacturing standards, a like-minded government, and grassroot support for the industry, there can be no doubt that Australia is poised to become a Medical Cannabis powerhouse. It’s a climactic time for the Medical Cannabis industry.

Research and Development 100

Research and Development Pharmaceutical Patients Medicine 100

PrestoDoctor

SEPTEMBER 6, 2023

It has been a go-to option for healthcare professionals seeking to manage pain effectively for their patients. This has led many patients to explore cannabis as a potential substitute for prescription codeine. Additionally, common side effects such as drowsiness, constipation, and respiratory depression can be burdensome for patients.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105